Brentuximab induced CD30⁺ cutaneous lymphoma responded to anti-PD1 treatment

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e147-e148. doi: 10.1111/jdv.15378. Epub 2019 Jan 15.

Authors

V Nikolaou¹, T Iliakis², L Marinos³, A Economidi¹, P Panayiotidis², D Rigopoulos¹, A J Stratigos¹

Affiliations

¹ Dermatology Department, Cutaneous Lymphoma Clinic, Medical School, "A. Sygros" Hospital for Skin Diseases, National & Kapodestrian University of Athens, Athens, 16121, Greece.
² Hematology Unit, 1st Propedeutic Department of Internal Medicine, Laikon General Hospital, Medical School, University of Athens, Athens, 11527, Greece.
³ Hemopathology Department, "Evangelismos" General Hospital, Athens, 10676, Greece.

PMID: 30520137
DOI: 10.1111/jdv.15378

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Brentuximab Vedotin
Hodgkin Disease / drug therapy*
Humans
Immunoconjugates / adverse effects*
Ki-1 Antigen / metabolism
Lymphoma, T-Cell, Cutaneous / chemically induced
Lymphoma, T-Cell, Cutaneous / drug therapy*
Lymphoma, T-Cell, Cutaneous / metabolism
Male
Nivolumab / therapeutic use*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Skin Neoplasms / chemically induced
Skin Neoplasms / drug therapy*
Skin Neoplasms / metabolism

Substances

Antineoplastic Agents, Immunological
Immunoconjugates
Ki-1 Antigen
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
Brentuximab Vedotin